I specialize in the care of patients with Hodgkin and non-Hodgkin lymphoma. I am Clinical Director of the Division of Hematologic Oncology and I am board-certified in internal medicine, medical oncology, and hematology. Recognizing that advances in medicine come about as a result of clinical research, I am the Principal Investigator for a number of clinical trials aimed at improving the care of patients with lymphoma. The findings of several of the clinical trials I have led have changed the international standard of care.
My research has focused on improving the outcome of patients with poor-risk diffuse large B cell lymphoma (DLBCL) and Hodgkin lymphoma (HL). This effort has been conducted along two tracks. One effort is focused on improving therapy for patients with disease that has returned or is not responding to standard therapy (refractory disease), through the use of high-dose therapy and autologous stem cell transplantation as well as new agents that can be incorporated into such “salvage” therapy.
A second approach involves developing strategies to optimize the treatment of newly diagnosed DLBCL according to the likelihood of their disease recurring (“risk-adapted therapy”), using what we have learned by studying patients with relapsed or refractory disease. We design risk-adapted therapy according to a patient’s risk factors before treatment (clinical, molecular, or pathologic features of the disease) and the results of imaging studies.
- Clinical Expertise: Hodgkin and Non-Hodgkin Lymphoma; Autologous Bone Marrow Transplantation for Lymphoma
- Awards and Honors: New York Magazine Top Doctors (2015, 2016)
- Languages Spoken: English
- Education: MD, Wayne State University School of Medicine
- Residencies: Bronx Municipal Hospital Center; Albert Einstein College of Medicine
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology; Hematology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Craig H. Moskowitz
- A Phase I Study of SGN-CD19B for Patients with Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
- A Phase IB Study of MK-3475 (Pembrolizumab) Immunotherapy in Patients with Myelodysplastic Syndromes and Lymphoma
- A Phase II Study of Pembrolizumab Immunotherapy in Patients with Recurrent or Persistent Classical Hodgkin Lymphoma
- A Phase II Study of RICE Chemotherapy with and without SGN19 in Patients with Recurrent or Persistent Diffuse B-Cell Lymphoma
- A Pilot Study of Brentuximab Vedotin with Chemotherapy and Radiation Therapy in Early-Stage Poor-Risk Newly Diagnosed Hodgkin Lymphoma
Clinical Trials Co-Investigated by Craig H. Moskowitz
- A Phase I Study of Ibrutinib plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
- A Phase I Study of Nivolumab (BMS-936558) Immunotherapy in Patients with Relapsed or Refractory Hematologic Cancers
- A Phase I/II Study of Brentuximab Vedotin plus Nivolumab Immunotherapy in Patients with Recurrent or Persistent Hodgkin Lymphoma
- A Phase Ib/II Study of Mocetinostat plus Brentuximab Vedotin in Patients with Recurrent or Persistent Hodgkin Lymphoma
- A Phase II Study of Brentuximab (SGN-35) Given Before and After Adriamycin, Vinblastine, and Dacarbazine Therapy in Older Adults with Untreated Hodgkin Lymphoma
- A Phase II Study of Pembrolizumab Immunotherapy after Stem Cell Transplantation for Recurrent or Persistent Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more